Investing

Design Therapeutics : DSGN

DSGN

Stock Data

$13.30

$0.30 (2.21%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Design Therapeutics, Inc. is a pioneering biopharmaceutical firm focused on crafting treatments for genetic disorders caused by nucleotide repeat expansions. With a keen eye on diseases like Friedreich Ataxia and Myotonic Dystrophy Type-1, the company is advancing its GeneTAC product candidates to address a range of conditions including Fragile X syndrome and Huntington disease. Founded in 2017 and based in Carlsbad, California, Design Therapeutics aims to transform the lives of patients suffering from these progressive diseases.

All Design Therapeutics Articles

1 Article

Lee Jackson | Nov 20, 2025 at 8:21 AM EST

Here Are Thursday’s Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More

Pre-Market Stock Futures: The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA | NVDA Price Prediction) blew out its…